“
TL;DR
The central result was that plasma TMAO levels were significantly lower in SAH patients on admission compared to controls, and TMAO was detectable in the CSF.
Acta Neurochirurgica · 9 authors, 3 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
The central result was that plasma TMAO levels were significantly lower in SAH patients on admission compared to controls, and TMAO was detectable in the CSF.
Blood samples were collected at baseline, and daily from SAH patients in the ICU for 14 days. CSF was collected when available from external ventricular drains. The central finding was that baseline plasma TMAO levels were significantly lower in SAH patients (1.7 μmol/L) compared to controls (2.9 μmol/L). TMAO was detectable in CSF (0.4 μmol/L) and correlated positively with plasma levels. No significant changes in plasma TMAO levels were observed over the 15-day observation period in SAH patients. The study had limitations including a small SAH sample size, decreasing sample counts over time, and the inability to determine the exact time of hemorrhage onset. The authors conclude that their results do not support the hypothesis that increased TMAO levels are present in SAH or associated with its complications, but instead show decreased levels.